한글목차

세계 듀얼 오렉신 수용체 길항제 시장의 잠재력은 병원 및 클리닉 시장과 소매 약국 시장에서의 기회로 인해 유망한 시장으로 평가받고 있습니다. 세계 듀얼 오렉신 수용체 길항제 시장은 2025년부터 2031년까지 CAGR 7.8%로 성장할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 불면증 유병률 증가, 더 나은 치료에 대한 수요 증가, 수면 장애에 대한 인식 증가입니다.

• Lucintel의 예측에 따르면, 유형별로는 Daridorexant가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
• 용도별로는 병원 및 클리닉이 높은 성장세를 보일 것으로 예상됩니다.
• 지역별로는 북미가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

듀얼 오렉신 수용체 길항제 시장의 새로운 동향

듀얼 오렉신 수용체 길항제 시장은 약리학의 발전, 수면장애 유병률 증가, 소비자 선호도 변화 등에 힘입어 많은 새로운 트렌드를 보이고 있습니다. 오렉신 수용체에 대한 지식이 깊어짐에 따라 다양한 환자들의 요구를 충족시킬 수 있는 새로운 적응증과 제형이 조사되고 있습니다. 이러한 추세는 DORA 시장의 미래를 이끌며 성장 기회를 창출하고 있습니다.

• 맞춤형 수면요법: DORA의 방향성 추세로 맞춤형 수면요법으로의 전환을 볼 수 있습니다. 연구의 발전에 따라 유전적 구조, 수면 행동, 다양한 병적 소인을 고려하여 환자의 요구사항에 맞게 맞춤화된 의약품이 증가하고 있습니다. 이러한 추세는 수면장애의 근본적인 원인을 해결하는 보다 효율적이고 개별화된 치료를 가능하게 하고, DORA 기반 의약품을 보다 효과적이고 안전하게 만들고 있습니다. 그 결과, 맞춤형 치료는 DORA 시장의 주요 구성요소가 되어 환자 맞춤형 솔루션을 제공하게 될 것입니다.
• 비 습관성 치료: 비 습관성 수면제에 대한 수요 증가가 DORA 시장을 주도하고 있습니다. DORA는 진정제나 벤조디아제핀 계열의 수면제와 달리 의존성이나 금단증상의 위험이 없습니다. 이 때문에 DORA는 중독의 위험 없이 장기적인 수면장애 치료를 원하는 환자들에게 점점 더 매력적으로 다가오고 있습니다. 기존 수면제 사용의 위험성에 대한 인식이 높아짐에 따라 DORA에 대한 수요는 특히 약물 의존에 대한 우려가 높은 국가에서 더욱 증가할 것으로 보입니다.
• 수면장애 병용요법: 불면증이나 기면증과 같은 복합적인 수면장애를 치료하기 위해 듀얼 오렉신 수용체 길항제와 다른 약물을 병용하는 것에 대한 관심이 증가하고 있으며, DORA를 항우울제나 항정신병약물 등 다른 치료제와 병용하면 전체 치료 효과를 높이고 여러 기저질환을 한 번에 치료할 수 있을 것으로 기대됩니다. 여러 기저질환을 한 번에 치료할 수 있을 것으로 기대되고 있습니다. 이러한 추세는 DORA 시장에 새로운 치료 기회를 제공하고, 더 심각한 건강 문제를 가진 환자들에게 완벽한 해결책을 제공할 수 있을 것으로 보입니다.
• 다른 질환에 대한 DORA 연구: DORA는 주로 수면장애에 활용되고 있지만, 다른 신경질환에 대한 치료 가능성을 모색하는 추세도 나타나고 있습니다. DORA가 각성과 각성에 관여하는 오렉신 수용체를 조절할 수 있기 때문에 DORA는 보다 광범위한 치료의 유력한 후보로 떠오르고 있으며, 불안, 우울증, 심지어 알츠하이머병과 같은 질병을 치료하는 데 DORA를 활용하는 방법을 발견하기 위한 연구가 진행 중입니다. 이러한 추세는 DORA의 시장을 더 크게 만들고, DORA를 신경 영역의 다목적 약물로 포지셔닝할 수 있습니다.
• 더 많은 의약품 승인 및 임상시험: DORA가 수면 장애 치료에 대한 효능을 계속 입증함에 따라 더 많은 임상시험이 수행되고 규제 당국은 더 많은 DORA 의약품을 승인하고 있습니다. 수면의 질을 개선하고 전 세계적으로 급증하는 수면 장애에 대한 관심이 높아짐에 따라 DORA 기반 치료에 투자하는 제약회사들이 늘어나고 있습니다. 이러한 추세는 치료 옵션을 늘리고, 신제품 출시와 임상 데이터 축적에 따른 시장 성장을 촉진할 것입니다.

개별화된 수면 치료, 비중독성 치료, 병용치료에 대한 연구 등 듀얼오렉신 수용체 길항제 시장의 새로운 트렌드는 업계 상황을 크게 변화시키고 있습니다. 이러한 추세는 수면장애에 대한 보다 효율적이고 안전한 개별화된 치료를 위한 지속적인 움직임을 보여주며, DORA 시장을 향후 몇 년 동안 미래 성장과 혁신으로 이끌 것으로 보입니다.

듀얼 오렉신 수용체 길항제 시장의 최근 동향

수면장애에 대한 연구 활동의 증가, 규제 당국의 승인, 제제 개발의 진전에 힘입어 최근 몇 년 동안 이중 옥신 수용체 길항제 시장은 큰 진전을 이루었습니다. 이러한 모든 발전은 DORA 기반 치료의 효능을 향상시키고, 수면장애 및 기타 이차적 합병증으로 고통받는 환자들에게 새로운 치료의 길을 제시하고 있습니다. 다음은 시장을 재편하고 있는 가장 중요한 신흥 개발 중 5가지를 소개합니다.

• FDA의 수볼렉산트 승인: 2014년 미국 FDA의 수볼렉산트(바르살라) 승인은 DORA 시장에 큰 이정표가 되었습니다. 이 카테고리의 첫 번째 치료제인 발살라는 현재 불면증 환자가 이용할 수 있는 가장 큰 치료 옵션 중 하나입니다. 이번 승인으로 DORA의 추가 개발의 길이 열렸으며, 수면 유도에서 오렉신 수용체 길항 작용의 효능이 더욱 강조되었습니다. 발살라의 성공은 다른 유망한 DORA 약물에 대한 추가 연구를 촉진하여 불면증 및 수면 장애에 대한 치료 옵션을 늘릴 수 있는 계기가 될 것입니다.
• 개발 중인 파이프라인 DORA 약물: 많은 제약회사들이 증가하는 수면제 수요를 충족시키기 위해 새로운 듀얼 오렉신 수용체 길항제를 개발하고 있습니다. 불면증, 기면증, 기타 수면 관련 질환 등의 치료에 대한 안전성과 유효성을 확인하기 위해 임상시험을 진행하고 있으며, DORA의 효능을 높이고 부작용을 줄이기 위한 끊임없는 연구를 통해 이러한 신약은 시장에 큰 영향을 미치고 환자들에게 더 많은 치료 옵션을 제공할 수 있습니다. 환자에게 더 많은 치료 옵션을 제공할 것으로 기대됩니다.
• DORA의 전 세계적인 가용성: DORA를 승인하는 국가가 증가함에 따라 DORA 세계 시장은 확대되고 있습니다. 수보렉산트는 이미 여러 국가에서 승인을 받았으며, 임상 데이터가 축적됨에 따라 더 많은 DORA 기반 약물이 승인될 가능성이 있습니다. 이러한 성장은 안전하고 효과적인 수면제에 대한 세계 수요 증가에 대응하는 데 도움이 될 것이며, DORA 치료제의 접근성이 높아짐에 따라 시장 경쟁력이 강화되고 전 세계 소비자의 치료가 개선될 것으로 기대됩니다.
• 비습관형성 요법의 중요성: 기존 진정제의 위험성에 대한 우려가 커지면서 비습관성 수면 보조제 개발에 중점을 두고 있습니다. 다른 수면제와 같은 의존성 위험이 없는 DORA가 그 선두주자입니다. 환자와 의료 전문가 모두 불면증 및 기타 수면 장애에 대한 보다 안전하고 장기적인 치료법을 찾고 있으며, DORA를 기반으로 한 치료법에 대한 수요가 증가하고 있습니다.
• DORA 적응증 확대 연구: DORA의 수면장애 외 적응증에 대한 연구가 가속화되고 있습니다. 불안장애, 우울증 등 신경-정신질환, 알츠하이머병 등 신경퇴행성 질환의 치료제로서의 가능성을 검토하고 있습니다. 이러한 연구가 성공한다면 DORA의 치료 영역이 비약적으로 확대되어 여러 질환의 치료에 새로운 패러다임을 제시할 수 있을 것으로 기대됩니다. 이러한 응용 범위의 확대는 시장 확대와 기술 혁신의 원동력이 될 것으로 보입니다.

듀얼 오렉신 수용체 길항제 시장에서 규제 당국의 승인, 신약 개발, 세계 접근성 확대와 같은 큰 진전은 수면장애 치료의 성장과 혁신으로 이어질 것입니다. 더 많은 약물이 시장에 출시되고 더 많은 적응증에 대한 연구가 진행되면 DORA 시장은 극적으로 확대되어 환자와 제약사 모두에게 이익이 될 것으로 보입니다.

목차

제1장 주요 요약

제2장 세계의 듀얼 오렉신 수용체 길항제 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 2019년부터 2031년까지 시장 동향과 예측 분석

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 듀얼 오렉신 수용체 길항제 시장 동향(2019-2024년)과 예측(2025-2031년)
• 유형별
  • Suvorexant
  • Lemborexant
  • Daridorexant
• 용도별
  • 병원·클리닉
  • 소매 약국
  • 기타

제4장 2019년부터 2031년까지 지역별 시장 동향과 예측 분석

• 지역별
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 유형별
  • 용도별
  • 지역별
• 세계의 듀얼 오렉신 수용체 길항제 시장의 최신 동향
• 전략 분석
  • 신제품 개발
  • 세계의 듀얼 오렉신 수용체 길항제 시장 생산능력 확대
  • 세계의 듀얼 오렉신 수용체 길항제 시장 합병, 인수, 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• Merck
• Eisal
• Idorsia
• Takeda

영문목차

The future of the global dual orexin receptor antagonist market looks promising with opportunities in the hospital & clinic and retail pharmacy markets. The global dual orexin receptor antagonist market is expected to grow with a CAGR of 7.8% from 2025 to 2031. The major drivers for this market are the rising prevalence of insomnia, the increasing demand for better treatments, and the growing awareness of sleep disorders.

• Lucintel forecasts that, within the type category, daridorexant is expected to witness the highest growth over the forecast period.
• Within the application category, hospital & clinic is expected to witness higher growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Dual Orexin Receptor Antagonist Market

The dual orexin receptor antagonist market is seeing a number of emerging trends, fueled by advancements in pharmacology, the rising incidence of sleep disorders, and changing consumer preferences. As knowledge about orexin receptors grows, new indications and drug formulations are being investigated to address various patient needs. These trends are guiding the future of the DORA market and creating opportunities for increased growth.

• Customized Sleep Therapies: A trend in DORA's direction is seen to move toward customized sleep therapies. With growing advancements in research, more medicines are being made personalized to fit patients' requirements specifically, considering their genetic structure, sleep behaviors, and predisposition to various medical conditions. This trend is making it possible to have more efficient and personalized treatments that address the underlying causes of sleep disorders, making DORA-based medicines more effective and safer. Consequently, personalized therapies will be a major component of the DORA market, providing patient-specific solutions.
• Non-Habit-Forming Treatments: Rising demand for non-habit-forming sleep medications is creating a drive in the DORA market. Unlike sedatives and benzodiazepines, DORAs have no risk of dependence or withdrawal symptoms associated with them. This has rendered DORAs increasingly appealing to patients who desire long-term remedies for sleep disorders without the risk of addiction. As people become more aware of the risks associated with the use of conventional sleep medicines, demand for DORAs will increase, particularly in countries where there is high concern about dependency on medications.
• Combination Therapies for Sleep Disorders: There is increasing interest in combining dual orexin receptor antagonists with other drug classes to treat complicated sleep disorders, such as insomnia and narcolepsy. By combining DORAs with other therapeutic drugs, such as antidepressants or antipsychotics, scientists are hoping to enhance the overall effectiveness of treatments and treat multiple underlying conditions at once. This trend will lead to new opportunities for therapy in the DORA market and give patients with more severe health problems complete solutions.
• DORA Research for Other Disorders: Even though DORAs are utilized mostly for sleep disorders, a trend is observed towards exploring their therapeutic potential in other neurological diseases. Studies are in progress to discover how to use DORAs in the treatment of diseases such as anxiety, depression, and even Alzheimer's. Since DORAs can modulate orexin receptors, which are involved in wakefulness and arousal, they are a strong contender for a broader therapy. This trend could make the market for DORAs much larger and position them as multi-purpose drugs within the neurological arena.
• More Regulatory Approvals and Clinical Trials: As DORAs continue to show their efficacy in the treatment of sleep disorders, more clinical trials are being undertaken and regulatory agencies are approving more DORA drugs. The growing interest in bettering the quality of sleep and tackling the worldwide surge in sleep disorders is causing more pharmaceutical firms to invest in DORA-based therapy. This trend should result in an increase in treatment options, fueling further market growth as new products emerge and clinical data continue to accrue.

The new trends in the dual orexin receptor antagonist market, including personalized sleep treatments, non-addictive treatments, and studies on combination treatments, are greatly transforming the industry landscape. These trends are indicative of a continued move towards more efficient, safer, and personalized treatments for sleep disorders, setting the DORA market up for future growth and innovation over the next few years.

Recent Developments in the Dual Orexin Receptor Antagonist Market

The dual orexin receptor antagonist market witnessed significant progress in recent years, fueled by rising research activity in sleep disorders, approvals from the regulatory authorities, and advancements in formulations. All these advances have enhanced the efficacy of DORA-based treatments, presenting patients suffering from sleep disorders and other secondary complications with new avenues for treatment. Five of the most significant developments that are remaking the market are discussed below.

• FDA Approval of Suvorexant: The US FDA approval of Suvorexant (Balsara) in 2014 was a major benchmark for the DORA market. As the inaugural drug of this category, Balsara is now one of the largest treatment options available to patients of insomnia. This endorsement has opened the door to additional development of DORAs and has highlighted further the effectiveness of orexin receptor antagonism in inducing sleep. The success of Balsara has encouraged further research into other promising DORA drugs, increasing the treatments available for insomnia and sleep disorders.
• Pipeline DORA Drugs in Development: A number of pharmaceutical firms are developing novel Dual Orexin Receptor Antagonists to meet the increasing demand for sleep medicines. The drugs are being tested in clinical trials to determine their safety and effectiveness in the treatment of diseases such as insomnia, narcolepsy, and other sleep-related disorders. With constant research aimed at enhancing the efficacy of DORAs and reducing side effects, these new drugs have the promise to make a significant impact on the market and offer more treatment alternatives for patients.
• DORA Availability Widening Globally: With increased countries approving DORA drugs, the global market for these drugs is widening. Suvorexant has already been licensed in some countries, and more DORA-based medications are likely to be licensed as clinical data continue to accumulate. This growth is assisting in meeting increasing global demand for safe and effective sleep medications. Greater availability of DORA medications will be expected to enhance market competitiveness and make for improved treatment for consumers globally.
• Emphasis on Non-Habit-Forming Therapies: As concerns about the dangers of conventional sedatives continue to grow, efforts are focused on creating non-habit-forming sleep aids. DORAs, which pose no risk of dependence like other sleeping medications, lead the charge. Patients and healthcare professionals alike are increasingly looking for safer long-term cures for insomnia and other sleep disorders, and recognizing this, demand for DORA-based therapies is increasing.
• Expanded Indications Research for DORAs: Research on the application of DORAs for indications other than sleep disorders is picking up speed. Investigations are looking into the possibility of these drugs being used to treat neurological and psychiatric diseases like anxiety, depression, and neurodegenerative conditions like Alzheimer's. If successful, these studies can drastically expand the therapeutic horizon for DORAs and result in new paradigms for the treatment of several diseases. This broadened application would fuel market expansion and innovation.

The major advancements in the dual orexin receptor antagonist market, such as regulatory approval, new drug development, and expanded global access, are leading the way towards additional growth and innovation in treating sleep disorders. With more drugs coming to the market and further research into more indications, the DORA market is set for dramatic expansion, to the advantage of both patients and pharmaceutical firms.

Strategic Growth Opportunities in the Dual Orexin Receptor Antagonist Market

The dual orexin receptor antagonist market offers many strategic growth opportunities in key applications, fueled by a growing awareness of sleep disorders and a growing emphasis on neurological health. These opportunities range across a number of therapeutic areas, from sleep disorders to psychiatric and neurological disorders, and are likely to define the future of the market.

• Growth in Emerging Markets: Emerging markets in Asia, Latin America, and Africa provide ample growth opportunities for the DORA market. With growing awareness of sleep disorders and increasing disposable incomes, demand for effective sleep aids is on the rise. Companies can customize their products to suit the particular requirements of these markets, increasing their reach through localized marketing channels and distribution networks.
• Expansion in Sleep Disorder Treatment: With the increasing incidence of sleep disorders such as insomnia, narcolepsy, and sleep apnea across the world, the market for dual orexin receptor antagonists is likely to grow. By targeting the enhancement of availability and affordability of DORA drugs for the treatment of sleep disorders, pharmaceutical companies can capitalize on this expanding market, particularly as more people look for non-habit-forming, effective treatments.
• Targeting Mental Health Disorders: Investigations into the potential application of DORAs in treating mental health disorders, including depression and anxiety, are creating new opportunities for market expansion. With the increasing demand for treatments that target both sleep disorders and psychiatric disorders, DORAs may provide a two-pronged approach to patient treatment. This potential makes DORAs central drugs for the treatment of sleep and mental health disorders.
• Emphasis on Personalized Medicine: Personalized medicine is taking center stage in the healthcare sector, and the DORA market is no different. By creating customized treatments that take into consideration patient-specific factors, including genetic factors and lifestyle, firms are able to maximize the safety and effectiveness of DORA-based medicines. This trend will propel market growth as patients are increasingly looking for customized treatment solutions that meet their specific needs.
• Combination Therapies with Wider Market Opportunities: Combination therapies of DORAs and other drug types, like antidepressants or antipsychotics, have considerable growth opportunities. These therapies have the goal to treat multiple basic conditions, for example, sleep disorders, anxiety, and depression, within one treatment protocol. Through the presentation of comprehensive remedies, combination therapies of DORAs have a wider market scope and can create new therapeutic avenues for complex diseased patients.

Strategic opportunities for growth in the dual orexin receptor antagonist market, fueled by emerging markets, mental health uses, personalized medicine, and combination therapies, will dramatically reshape the market landscape. Companies that target these opportunities will be well-positioned to succeed in this dynamic and fast-growing market.

Dual Orexin Receptor Antagonist Market Driver and Challenges

The dual orexin receptor antagonist market is influenced by several drivers and challenges such as technological innovations, economic considerations, and regulatory aspects. While they drive the market growth, they also pose challenges that have to be tackled by manufacturers. Through knowledge of these major drivers and challenges, companies can set themselves up for success.

The factors responsible for driving the dual orexin receptor antagonist market include:

1. Increasing Incidence of Sleep Disorders: With the global incidence of sleep disorders, including insomnia and narcolepsy, on the rise, there is a growing need for effective treatments such as dual orexin receptor antagonists. DORAs offer a novel and non-habit-forming alternative to conventional sedatives, fueling market growth.

2. Drug Formulation Innovations: Advances in drug technology are making it possible to develop more potent and targeted DORA-based medications. Innovative formulations that enhance the safety and effectiveness of the drugs are drawing in customers and healthcare professionals, driving the market further.

3. Increased Emphasis on Mental Health: The increased emphasis on mental health and its relationship with sleep disorders is fueling demand for DORA therapies. Addressing both sleep and psychological ailments, DORAs are now being recognized as a feasible treatment option, which is broadening their market scope.

4. Increasing Healthcare Spending: Increasing healthcare spending worldwide is driving the growth of the DORA market, as patients are increasingly opting for medical treatment for their sleep disorders. With increasing disposable income, patients are becoming more inclined to spend money on sophisticated treatments that provide long-term results.

5. Enlarging Clinical Research: Continuous clinical research into the therapeutic potential of DORAs for other neurological and psychiatric disorders, as well as sleep disorders, is a major growth driver for the market. With new indications for DORAs arising, the market for these medications is likely to grow.

Challenges in the dual orexin receptor antagonist market are:

1. Regulatory Hurdles: The regulatory process for the approval of DORA drugs is time-consuming and complex, especially in countries with strict pharmaceutical regulations. Companies need to overcome these issues to market their drugs on time.

2. Emerging Markets' Price Sensitivity: With demand for DORAs growing, price sensitivity is an area of difficulty, particularly in the emerging markets. Firms need to juggle the accessibility of their product alongside ensuring the same high level of quality and efficacy.

3. Alternative Treatment Competition: The DORA market competes with alternative treatments for sleep disorders, including benzodiazepines, melatonin, and other sedatives. Companies need to differentiate DORA-based therapies from these alternatives to remain competitive.

The challenges and drivers affecting the dual orexin receptor antagonist market mirror the dynamic nature of the sector. Although increased awareness, formulation advancements, and rising healthcare investment are fueling growth, regulatory barriers and price sensitivity remain current challenges. By addressing these variables, companies can more effectively deal with the intricacies of the market and take advantage of emerging opportunities.

List of Dual Orexin Receptor Antagonist Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies dual orexin receptor antagonist companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dual orexin receptor antagonist companies profiled in this report include-

• Merck
• Eisal
• Idorsia
• Takeda

Dual Orexin Receptor Antagonist Market by Segment

The study includes a forecast for the global dual orexin receptor antagonist market by type, application, and region.

Dual Orexin Receptor Antagonist Market by Type [Value from 2019 to 2031]:

• Suvorexant
• Lemborexant
• Daridorexant

Dual Orexin Receptor Antagonist Market by Application [Value from 2019 to 2031]:

• Hospital & Clinic
• Retail Pharmacies
• Others

Dual Orexin Receptor Antagonist Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Dual Orexin Receptor Antagonist Market

The market for dual orexin receptor antagonist (DORA) has been expanding very quickly as a result of increasing interest in sleep disorders like insomnia and other neurological conditions associated with it. This category of drugs, acting on the orexin receptors involved in wakefulness regulation, is gaining popularity across the world because of its efficiency in inducing sleep without side effects compared to conventional sedatives. Major developments in the DORA market have been noted in key pharma markets such as the United States, China, Germany, India, and Japan, where research, clinical trials, and product approvals remain to define the market scenario.

• United States: In the United States, the market for dual orexin receptor antagonist has experienced considerable growth, especially with the regulatory approval of products such as Suvorexant (Balsara), the first DORA to be approved by the FDA for the treatment of insomnia. An increased need for effective treatments, fueled by the rising incidence of sleep disorders, has driven further interest in DORAs. U.S. market is marked by swift uptake of novel sleep aids, with continuous research aimed at enhancing the safety and effectiveness of the drugs. The regulatory environment is favorable, offering a clear line for further DORA drugs to come into the market.
• China: China is experiencing swift growth in the market for DORA as awareness about sleep disorders rises and more attention is being focused on mental health. The Chinese government has been investing in healthcare infrastructure, and increasing numbers of people are looking for treatments for insomnia and associated conditions. Although DORAs are relatively new to the market, consumers are increasingly interested in innovative sleep aids. Clinical trials and research are ongoing, and the market is likely to grow as the demand for safe and effective treatment for sleep disorders grows nationwide.
• Germany: Germany's DORA market is expanding steadily, with growing awareness of sleep disorders such as insomnia and narcolepsy. With the healthcare system providing significant support for mental health conditions, Germany has emerged as a leading market for the uptake of new treatments. Regulatory approvals for DORAs like Suvorexant and other upcoming drugs have improved treatment options for patients. Germany is targeting the betterment of sleeping quality and encouragement of safer alternatives to conventional sedatives. Having robust pharmaceutical corporations in Germany enhances ongoing research and development in this sector.
• India: In India, the DORA market remains nascent with very limited presence of orexin receptor-targeted drugs for sleeping disorders. Nonetheless, with the rising prevalence of insomnia and increased awareness of mental illness, there is a growing demand for successful treatments. The market is dominated by the embracement of Western medicine, yet there is a desire for cheaper drugs. Regulatory authorities in India are considering the approval of DORAs, and the market is expected to expand as knowledge of the advantages of DORA-based therapies spreads among the healthcare community and consumers.
• Japan: Japan has experienced strong growth in the DORA market, especially with the rising incidence of sleep disorders due to lifestyle and aging populations. Japanese pharmaceutical firms are at the forefront of creating DORA-based treatments, including the approval of Suvorexant. The need for safe and non-habit-forming sleep aids is increasing, and DORAs are a very promising treatment option. Japan's strong healthcare system and regulatory environment facilitate the ongoing development of this market. The emphasis is on providing effective treatments that ensure healthy sleep without the threat of dependence.

Features of the Global Dual Orexin Receptor Antagonist Market

Market Size Estimates: Dual orexin receptor antagonist market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Dual orexin receptor antagonist market size by type, application, and region in terms of value ($B).

Regional Analysis: Dual orexin receptor antagonist market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the dual orexin receptor antagonist market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dual orexin receptor antagonist market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the dual orexin receptor antagonist market by type (suvorexant, lemborexant, and daridorexant), application (hospital & clinic, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Dual Orexin Receptor Antagonist Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Dual Orexin Receptor Antagonist Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Dual Orexin Receptor Antagonist Market by Type
  • 3.3.1: Suvorexant
  • 3.3.2: Lemborexant
  • 3.3.3: Daridorexant
• 3.4: Global Dual Orexin Receptor Antagonist Market by Application
  • 3.4.1: Hospital & Clinic
  • 3.4.2: Retail Pharmacies
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Dual Orexin Receptor Antagonist Market by Region
• 4.2: North American Dual Orexin Receptor Antagonist Market
  • 4.2.1: North American Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.2.2: North American Market by Application: Hospital & Clinic, Retail Pharmacies, and Others
• 4.3: European Dual Orexin Receptor Antagonist Market
  • 4.3.1: European Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.3.2: European Market by Application: Hospital & Clinic, Retail Pharmacies, and Others
• 4.4: APAC Dual Orexin Receptor Antagonist Market
  • 4.4.1: APAC Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.4.2: APAC Market by Application: Hospital & Clinic, Retail Pharmacies, and Others
• 4.5: ROW Dual Orexin Receptor Antagonist Market
  • 4.5.1: ROW Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.5.2: ROW Market by Application: Hospital & Clinic, Retail Pharmacies, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Dual Orexin Receptor Antagonist Market by Type
  • 6.1.2: Growth Opportunities for the Global Dual Orexin Receptor Antagonist Market by Application
  • 6.1.3: Growth Opportunities for the Global Dual Orexin Receptor Antagonist Market by Region
• 6.2: Emerging Trends in the Global Dual Orexin Receptor Antagonist Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Dual Orexin Receptor Antagonist Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Dual Orexin Receptor Antagonist Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Merck
• 7.2: Eisal
• 7.3: Idorsia
• 7.4: Takeda